Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 10.9%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) shares traded down 10.9% during trading on Thursday . The company traded as low as $13.18 and last traded at $13.54. 1,255,054 shares changed hands during mid-day trading, an increase of 62% from the average session volume of 776,140 shares. The stock had previously closed at $15.19.

Wall Street Analysts Forecast Growth

DAWN has been the topic of several research analyst reports. Oppenheimer reissued a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Wedbush restated an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating on the stock in a research note on Tuesday, February 27th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday. Finally, Piper Sandler reiterated an "overweight" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $39.33.

Day One Biopharmaceuticals Stock Performance

The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -5.68 and a beta of -1.48. The business has a 50-day simple moving average of $15.28 and a two-hundred day simple moving average of $13.79.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). Research analysts predict that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 2,258 shares of the business's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now owns 1,244,662 shares of the company's stock, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total value of $322,200.00. Following the sale, the insider now directly owns 1,224,662 shares of the company's stock, valued at approximately $19,729,304.82. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the transaction, the insider now owns 1,244,662 shares of the company's stock, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of DAWN. Vanguard Group Inc. raised its stake in Day One Biopharmaceuticals by 8.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company's stock valued at $56,807,000 after purchasing an additional 346,090 shares during the last quarter. Franklin Resources Inc. grew its stake in Day One Biopharmaceuticals by 4.2% in the 4th quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company's stock worth $61,857,000 after acquiring an additional 169,463 shares during the period. Braidwell LP lifted its stake in shares of Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company's stock worth $61,547,000 after purchasing an additional 500,000 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company's stock valued at $30,935,000 after purchasing an additional 472,654 shares during the period. Finally, Polar Capital Holdings Plc increased its stake in Day One Biopharmaceuticals by 9.0% in the third quarter. Polar Capital Holdings Plc now owns 1,935,000 shares of the company's stock valued at $23,742,000 after purchasing an additional 160,385 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.